Yamamoto N - Search Results

1

Pharmacokinetic and dose-finding study of osimertinib in patients with impaired renal function and low body weight.

Fujiwara Y, Makihara R, Hase T, Hashimoto N, Naito T, Tsubata Y, Okuno T, Takahashi T, Kobayashi H, Shinno Y, Zenke Y, Ikeda T, Hosomi Y, Watanabe K, Kitazono S, Sakiyama N, Makino Y, Yamamoto N. Fujiwara Y, et al. Among authors: yamamoto n. Cancer Sci. 2023 May;114(5):2087-2097. doi: 10.1111/cas.15736. Epub 2023 Feb 14. Cancer Sci. 2023. PMID: 36704833 Free PMC article.

2

Phase I study of cisplatin, vinorelbine, and concurrent thoracic radiotherapy for unresectable stage III non-small cell lung cancer.

Sekine I, Noda K, Oshita F, Yamada K, Tanaka M, Yamashita K, Nokihara H, Yamamoto N, Kunitoh H, Ohe Y, Tamura T, Kodama T, Sumi M, Saijo N. Sekine I, et al. Among authors: yamamoto n. Cancer Sci. 2004 Aug;95(8):691-5. doi: 10.1111/j.1349-7006.2004.tb03331.x. Cancer Sci. 2004. PMID: 15298734 Free article. Clinical Trial.

3

A phase I study and pharmacologic evaluation of irinotecan and carboplatin for patients with advanced ovarian carcinoma who previously received platinum-containing chemotherapy.

Yonemori K, Katsumata N, Yamamoto N, Kasamatsu T, Yamada T, Tsunematsu R, Fujiwara Y. Yonemori K, et al. Among authors: yamamoto n. Cancer. 2005 Sep 15;104(6):1204-12. doi: 10.1002/cncr.21287. Cancer. 2005. PMID: 16047343 Free article. Clinical Trial.

4

Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumors.

Yamamoto N, Horiike A, Fujisaka Y, Murakami H, Shimoyama T, Yamada Y, Tamura T. Yamamoto N, et al. Cancer Chemother Pharmacol. 2008 Mar;61(3):489-96. doi: 10.1007/s00280-007-0494-8. Epub 2007 May 5. Cancer Chemother Pharmacol. 2008. PMID: 17483950 Clinical Trial.

5

Serum total bilirubin as a predictive factor for severe neutropenia in lung cancer patients treated with cisplatin and irinotecan.

Fujiwara Y, Sekine I, Ohe Y, Kunitoh H, Yamamoto N, Nokihara H, Simmyo Y, Fukui T, Yamada K, Tamura T. Fujiwara Y, et al. Among authors: yamamoto n. Jpn J Clin Oncol. 2007 May;37(5):358-64. doi: 10.1093/jjco/hym033. Epub 2007 May 30. Jpn J Clin Oncol. 2007. PMID: 17538190

6

Phase I clinical and pharmacokinetic study of 3-weekly, 3-h infusion of ixabepilone (BMS-247550), an epothilone B analog, in Japanese patients with refractory solid tumors.

Shimizu T, Yamamoto N, Yamada Y, Fujisaka Y, Yamada K, Fujiwara Y, Takayama K, Tokudome T, Klimovsky J, Tamura T. Shimizu T, et al. Among authors: yamamoto n. Cancer Chemother Pharmacol. 2008 Apr;61(5):751-8. doi: 10.1007/s00280-007-0530-8. Epub 2007 Jun 27. Cancer Chemother Pharmacol. 2008. PMID: 17594093 Clinical Trial.

7

Effect of platinum combined with irinotecan or paclitaxel against large cell neuroendocrine carcinoma of the lung.

Fujiwara Y, Sekine I, Tsuta K, Ohe Y, Kunitoh H, Yamamoto N, Nokihara H, Yamada K, Tamura T. Fujiwara Y, et al. Among authors: yamamoto n. Jpn J Clin Oncol. 2007 Jul;37(7):482-6. doi: 10.1093/jjco/hym053. Epub 2007 Jul 24. Jpn J Clin Oncol. 2007. PMID: 17652109

8

Circulating endothelial cells in non-small cell lung cancer patients treated with carboplatin and paclitaxel.

Kawaishi M, Fujiwara Y, Fukui T, Kato T, Yamada K, Ohe Y, Kunitoh H, Sekine I, Yamamoto N, Nokihara H, Watabe T, Shimoda Y, Arao T, Nishio K, Tamura T, Koizumi F. Kawaishi M, et al. Among authors: yamamoto n. J Thorac Oncol. 2009 Feb;4(2):208-13. doi: 10.1097/JTO.0b013e318193030d. J Thorac Oncol. 2009. PMID: 19179898 Free article.

9

Phase I and pharmacokinetic study of HER2-targeted rhuMAb 2C4 (Pertuzumab, RO4368451) in Japanese patients with solid tumors.

Yamamoto N, Yamada Y, Fujiwara Y, Yamada K, Fujisaka Y, Shimizu T, Tamura T. Yamamoto N, et al. Jpn J Clin Oncol. 2009 Apr;39(4):260-6. doi: 10.1093/jjco/hyp006. Epub 2009 Mar 4. Jpn J Clin Oncol. 2009. PMID: 19261664 Free PMC article. Clinical Trial.

10

Phase I, dose escalation and pharmacokinetic study of cediranib (RECENTIN), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors.

Yamamoto N, Tamura T, Yamamoto N, Yamada K, Yamada Y, Nokihara H, Fujiwara Y, Takahashi T, Murakami H, Boku N, Yamazaki K, Puchalski TA, Shin E. Yamamoto N, et al. Cancer Chemother Pharmacol. 2009 Nov;64(6):1165-72. doi: 10.1007/s00280-009-0979-8. Epub 2009 Mar 24. Cancer Chemother Pharmacol. 2009. PMID: 19308410 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

6,236 results

Search Page